Empagliflozin PBS listing expanded to patients with high CV risk regardless of HbA1c level
It follows a similar change affecting dapagliflozin last year.
Patients with type 2 diabetes at high risk of cardiovascular events now have access to PBS-funded empagliflozin, whatever their HbA1c levels.
The new PBS listing lets doctors initiate empagliflozin in combination with metformin for type 2 diabetes patients with existing CVD, high cardiovascular risk or who are Indigenous.
